<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: In mammals, proper storage and distribution of <z:chebi fb="23" ids="18059">lipids</z:chebi> in and between tissues is essential for the maintenance of energy homeostasis </plain></SENT>
<SENT sid="1" pm="."><plain>In contrast, aberrantly high levels of <z:chebi fb="4" ids="17855">triglycerides</z:chebi> in the blood ("<z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo>") represent a hallmark of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>As <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo> has been identified as an important risk factor for cardiovascular complications, in this study we aimed to identify molecular mechanisms in aberrant <z:chebi fb="0" ids="17855">triglyceride</z:chebi> elevation under these conditions </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: To determine the importance of hepatic <z:chebi fb="23" ids="18059">lipid</z:chebi> handling for systemic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, we profiled the expression patterns of various hepatic <z:chebi fb="23" ids="18059">lipid</z:chebi> transporters and receptors under healthy and type 2 diabetic conditions </plain></SENT>
<SENT sid="4" pm="."><plain>A differentially expressed <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> receptor was functionally characterized by generating <z:hpo ids='HP_0011009'>acute</z:hpo>, liver-specific loss- and gain-of-function animal models </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: We show that the hepatic expression of <z:chebi fb="23" ids="18059">lipid</z:chebi> transporter lipolysis-stimulated <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> receptor (LSR) is specifically impaired in mouse models of <z:hpo ids='HP_0001513'>obesity</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and can be restored by leptin replacement </plain></SENT>
<SENT sid="6" pm="."><plain>Experimental imitation of this pathophysiological situation by liver-specific knockdown of LSR promotes <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo> and elevated <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> (Apo)B and E serum levels in lean <z:mp ids='MP_0002169'>wild-type</z:mp> and ApoE knockout mice </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, genetic restoration of LSR expression in <z:mp ids='MP_0001261'>obese</z:mp> animals to <z:mp ids='MP_0002169'>wild-type</z:mp> levels improves serum <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels and serum profiles in these mice </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: The dysregulation of hepatic LSR under <z:mp ids='MP_0001261'>obese</z:mp> and diabetic conditions may provide a molecular rationale for systemic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and represent a novel target for alternative treatment strategies in these patients </plain></SENT>
</text></document>